Showing results (1-10 of 136) with videos related to
Sort By:
Pageof 14
Current Opinion in Immunology|March 27, 2018
Engineering T cells for adoptive therapy: outsmarting the tumorAndre Kunert, Reno DebetsImmunotherapy|June 13, 2015
Adoptive T-cell therapy: a need for standard immune monitoringYarne Klaver, Andre Kunert, Stefan Sleijfer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
T-cell Receptors for Clinical Therapy: In Vitro Assessment of Toxicity RiskAndre Kunert, Matthias Obenaus, Cor H J Lamers, et al.Frontiers in Immunology|November 23, 2013
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuAndre Kunert, Trudy Straetemans, Coen Govers, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 5, 2016
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell ResponsesAndre Kunert, Mandy van Brakel, Sabine van Steenbergen-Langeveld, et al.Immunotherapy|July 9, 2013
Genetically modified T lymphocytes: more than just direct effectorsCor H J Lamers, Reno DebetsJournal of Immunology (Baltimore, Md. : 1950)|November 25, 2022
Detection of Low-Frequency Epitope-Specific T Cells in Blood of Healthy Individuals according to an Optimized In Vitro Amplification SystemShweta Mahajan, Dian Kortleve, Reno Debets, et al.Seminars in Immunology|March 22, 2016
TCR-engineered T cells to treat tumors: Seeing but not touching?Reno Debets, Emmanuel Donnadieu, Salem Chouaib, et al.Molecular Cancer|October 17, 2025
Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapyRui M L Coelho, Reno Debets, Dora HammerlTrends in Immunology|April 13, 2022
Cancer germline antigens and tumor-agnostic CD8+ T cell evasionDian Kortleve, Rui M L Coelho, Dora Hammerl, et al.Pageof 14